» Articles » PMID: 24778411

Schizophrenia--time to Commit to Policy Change

Abstract

Care and outcomes for people with schizophrenia have improved in recent years, but further progress is needed to help more individuals achieve an independent and fulfilled life. This report sets out the current need, informs policy makers and all relevant stakeholders who influence care quality, and supports their commitment to creating a better future. The authors recommend the following policy actions, based on research evidence, stakeholder consultation, and examples of best practice worldwide. (1) Provide an evidence-based, integrated care package for people with schizophrenia that addresses their mental and physical health needs. (2) Provide support for people with schizophrenia to enter and to remain in their community, and develop mechanisms to help guide them through the complex benefit and employment systems. (3) Provide concrete support, information, and educational programs to families and carers on how to enhance care for an individual living with schizophrenia in a manner that entails minimal disruption to their lives. (4) All stakeholders, including organizations that support people living with schizophrenia, should be consulted to regularly revise, update, and improve policy on the management of schizophrenia. (5) Provide support, which is proportionate to the impact of the disease, for research and development of new treatments. (6) Establish adequately funded, ongoing, and regular awareness-raising campaigns that form an integral part of routine plans of action. Implementation of the above recommendations will require engagement by every stakeholder, but with commitment from all, change can be achieved.

Citing Articles

Real-life functioning and duration of illness in schizophrenia: A mediation analysis.

Brasso C, Bellino S, Bozzatello P, Montemagni C, Rocca P Heliyon. 2025; 11(1):e41332.

PMID: 39958743 PMC: 11825250. DOI: 10.1016/j.heliyon.2024.e41332.


Should we consider microbiota-based interventions as a novel therapeutic strategy for schizophrenia? A systematic review and meta-analysis.

Hassib L, Kanashiro A, Pedrazzi J, Vercesi B, Higa S, Arruda I Brain Behav Immun Health. 2025; 43():100923.

PMID: 39839986 PMC: 11745983. DOI: 10.1016/j.bbih.2024.100923.


Differential Expression of miR-26b-5p, EGR1, and STAT1 in Peripheral Blood of Schizophrenia Patients.

Liu Y, Qin F, Yu L, Zhao X, Long Q, Ma X Psychiatry Clin Psychopharmacol. 2025; 34(4):275-284.

PMID: 39772290 PMC: 11744383. DOI: 10.5152/pcp.2024.24882.


Investigating the causal pathways among psychopathological variables, cognitive impairment, and real-life functioning in people with schizophrenia.

Giuliani L, Sanmarchi F, Mucci A, Rucci P, Caporusso E, Bucci P Schizophrenia (Heidelb). 2025; 11(1):1.

PMID: 39753575 PMC: 11698981. DOI: 10.1038/s41537-024-00545-2.


Abnormalities in rich-club connections are associated with an exacerbation of genetic susceptibility to schizophrenia.

Li Y, Sun E, Dai R, Chen J, Huang H, Shan X BMC Psychiatry. 2024; 24(1):951.

PMID: 39731072 PMC: 11673898. DOI: 10.1186/s12888-024-06411-w.


References
1.
Taylor D, Young C, Paton C . Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry. 2003; 64(1):30-4. DOI: 10.4088/jcp.v64n0107. View

2.
McCabe R, Bullenkamp J, Hansson L, Lauber C, Martinez-Leal R, Rossler W . The therapeutic relationship and adherence to antipsychotic medication in schizophrenia. PLoS One. 2012; 7(4):e36080. PMC: 3338634. DOI: 10.1371/journal.pone.0036080. View

3.
Kooyman I, Dean K, Harvey S, Walsh E . Outcomes of public concern in schizophrenia. Br J Psychiatry Suppl. 2007; 50:s29-36. DOI: 10.1192/bjp.191.50.s29. View

4.
Aagaard J, Muller-Nielsen K . Clinical outcome of assertive community treatment (ACT) in a rural area in Denmark: a case-control study with a 2-year follow-up. Nord J Psychiatry. 2010; 65(5):299-305. DOI: 10.3109/08039488.2010.544405. View

5.
Zipursky R, Menezes N, Streiner D . Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res. 2013; 152(2-3):408-14. DOI: 10.1016/j.schres.2013.08.001. View